Auriga Maintains a 'Hold' on ViroPharma (VPHM); Generic Competition in Vancocin

Auriga maintains a 'Hold' on ViroPharma (NASDAQ: VPHM) price target of $19.00.

Analyst, Difei Yang, said, "Three generic Vancocin products were granted FDA approvals yesterday and at least two are shipping products. We do not expect Viropharma's request for preliminary injunction to be granted and thus expect full blown generic erosion to the Vancocin business immediately. We expect high volatility of the share price over the next few weeks as legal actions play out and we would advise our clients to stay on the sidelines."

For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.

Shares of ViroPharma closed at $22.44 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald